Screener
iRadimed IRMD EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by iRadimed in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: iRadimed’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029325
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Provision for income tax expense | 1,951 | 1,258 |
| Net income | $5,818 | $4,687 |
| Net income per share: | ||
| Basic | $0.46 | $0.37 |
| Diluted | $0.45 | $0.37 |
| Weighted average shares outstanding: | ||
| Basic | 12,783 | 12,714 |
| Diluted | 12,870 | 12,826 |
Item 1. Condensed Financial Statements
FAQ
- What is iRadimed's EPS (diluted)?
- iRadimed (IRMD) reported EPS (diluted) of $0.45 in Q1 2026.
- How has iRadimed's EPS (diluted) changed year-over-year?
- iRadimed's EPS (diluted) increased by 21.6% year-over-year, from $0.37 to $0.45.
- What is the long-term trend for iRadimed's EPS (diluted)?
- Over 4 years (2021 to 2025), iRadimed's EPS (diluted) has grown at a 24.0% compound annual growth rate (CAGR), from $0.74 to $1.75.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about iRadimed's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude